Arginine/lysine

Arginine/lysine, sold under the brand name LysaKare, is a fixed-dose combination medication used to protect the kidneys from radiation damage during cancer treatment with a radioactive medicine called lutetium (¹⁷⁷Lu) oxodotreotide.[1] It contains L-arginine hydrochloride and L-lysine hydrochloride.[1]

Arginine/lysine

Combination of
Arginine	Amino acid
Lysine	Amino acid
Clinical data
Trade names	LysaKare
License data	EU EMA: by INN
Routes of administration	Intravenous infusion
ATC code	V03AF11 (WHO)
Legal status
Legal status	EU: Rx-only

The most common side effects include nausea and vomiting.[1] Arginine/lysine is also associated with hyperkalaemia (high blood potassium levels), but the frequency of this side effect is not known.[1] Side effects with arginine/lysine are usually mild or moderate.[1]

Radiation from lutetium (¹⁷⁷Lu) oxodotreotide can cause damage when the medicine passes through tubules in the kidney.[1] Arginine and lysine interfere with the passage of lutetium (¹⁷⁷Lu) oxodotreotide through these kidney tubules.[1] As a result, the radioactive medicine leaves the body in the urine and the kidneys are exposed to less radiation.[1]

Arginine/lysine was approved for medical use in the European Union in July 2019.[1]

Medical uses

Arginine/lysine is indicated for reduction of renal radiation exposure during peptide receptor radionuclide therapy (PRRT) with lutetium (¹⁷⁷Lu) oxodotreotide in adults.[1]

References

1. "LysaKare EPAR". European Medicines Agency (EMA). 24 May 2019. Retrieved 22 July 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

External links

• "Arginine". Drug Information Portal. U.S. National Library of Medicine.
• "Lysine". Drug Information Portal. U.S. National Library of Medicine.